2,478 results match your criteria Prescrire International [Journal]


Pharmaceutical research and development: a new system is needed.

Authors:

Prescrire Int 2017 May;26(182):130-135

The system in operation since the late 20th cen- tury for stimulating pharmaceutical research and development (R&D) is increasingly showing seri- ous limitations. In particular, the new drugs it pro- duces are unaffordable and often offer only minor or even no benefits to patients. This system is under increasing criticism, not only from non-governmental organisations, but also from international institutions. Read More

View Article

Download full-text PDF

Source

Thrombophilia: Testing rarely useful after a venous thromboembolic event.

Authors:

Prescrire Int 2017 May;26(182):129

Some people have coagulation abnormalities, collectively referred to as thrombophilia, which increase the risk of thrombosis. What are the most frequently detected thrombophilia? Does throm- bophilia testing after a venous thromboembolic event enable effective adjustment of the treatment strategy?To answer these questions, we reviewed the available evidence using the standard Prescrire methodology. The best known inherited thrombophilia includes the factorV Leiden mutation and the prothrombin G20210A mutation. Read More

View Article

Download full-text PDF

Source
May 2017
1 Read

Rosacea First-choice treatments.

Authors:

Prescrire Int 2017 May;26(182):126-128

View Article

Download full-text PDF

Source

Adverse effects of short-course corticosteroids in children.

Authors:

Prescrire Int 2017 May;26(182):125

View Article

Download full-text PDF

Source
May 2017
1 Read

Natalizumab: retinal necrosis.

Authors:

Prescrire Int 2017 May;26(182):124

View Article

Download full-text PDF

Source
May 2017
1 Read

Drug-induced excess hair growth.

Authors:

Prescrire Int 2017 May;26(182):122-124

View Article

Download full-text PDF

Source
May 2017
1 Read

Insulin degludec + liraglutide (Xultophy°) in type 2 diabetes.

Authors:

Prescrire Int 2017 May;26(182):121

View Article

Download full-text PDF

Source

Carfilzomib (Kyprolis°) in multiple myeloma.

Authors:

Prescrire Int 2017 May;26(182):120

View Article

Download full-text PDF

Source
May 2017
1 Read

Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.

Authors:

Prescrire Int 2017 May;26(182):118-119

View Article

Download full-text PDF

Source

Sufentanil sublingual tablets (Zalviso°) and postoperative analgesia.

Authors:

Prescrire Int 2017 May;26(182):117-118

View Article

Download full-text PDF

Source
May 2017
1 Read

Towards better patient care: drugs to avoid in 2017.

Authors:

Prescrire Int 2017 Apr;26(181):108-111

To help healthcare professionals and patients choose high-quality treatments that minimise the risk of adverse effects, in early 2017 we updated the list of drugs that Prescrire advises health pro- fessionals and patients to avoid. Prescire's assessments of the harm-benefit balance of new drugs and indications are based on a rigorous procedure that includes a systematic and reproducible literature search, identification of patient-relevant outcomes, prioritisation of the supporting data based on the strength of evidence, comparison with standard treatments, and an analysis of both known and potential adverse effects. This fifth annual review of drugs to avoid has been extended to cover all drugs examined by Prescrire between 2010 and 2016 and authorised in the European Union, whereas previous reviews only considered drugs marketed in France. Read More

View Article

Download full-text PDF

Source
April 2017
1 Read

Digoxin.

Authors:

Prescrire Int 2017 Apr;26(181):107

View Article

Download full-text PDF

Source

Fractures related to bone fragility: prevention First-choice treatments.

Authors:

Prescrire Int 2017 Apr;26(181):103-106

View Article

Download full-text PDF

Source

Unborn children still exposed to NSAIDs.

Authors:

Prescrire Int 2017 Apr;26(181):102

View Article

Download full-text PDF

Source
April 2017
1 Read

Drug-induced posterior reversible encephalopathy syndrome.

Authors:

Prescrire Int 2017 Apr;26(181):98-101

Posterior reversible encephalopathy syndrome (PRES) is a serious neurological disorder consisting of headache, visual disturbances, seizures, impaired consciousness and radiological evidence of poster- ior cerebral oedema. It is occasionally complicated by cerebral haemorrhage or ischaemia. The main known risk factors for PRES are hypertension, pre-eclampsia, eclampsia, acute kid- ney injury and numerous drugs. Read More

View Article

Download full-text PDF

Source
April 2017
1 Read

Ciclosporin eye drops (Ikervis°) and dry eye syndrome.

Authors:

Prescrire Int 2017 Apr;26(181):96-97

View Article

Download full-text PDF

Source
April 2017
8 Reads

Adalimumab (Humira°) and hidradenitis suppurativa.

Authors:

Prescrire Int 2017 Apr;26(181):94-96

View Article

Download full-text PDF

Source
April 2017
1 Read

Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.

Authors:

Prescrire Int 2017 Apr;26(181):93-94

View Article

Download full-text PDF

Source
April 2017
1 Read

INN Common stem: -onidine.

Authors:

Prescrire Int 2017 Apr;26(181):92

View Article

Download full-text PDF

Source

Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis.

Authors:

Prescrire Int 2017 Apr;26(181):89-92

View Article

Download full-text PDF

Source

Osteoarthritis of the knee.

Authors:

Prescrire Int 2017 Mar;26(180):78

As of mid-2016, there is still no evidence that hyaluronic acid is more effective than placebo in osteoarthritis of the knee. It does however have adverse effects. Read More

View Article

Download full-text PDF

Source
March 2017
1 Read

Graves' disease in adults Antithyroid drugs, radioactive iodine, or sometimes thyroidectomy.

Authors:

Prescrire Int 2017 Mar;26(180):72-77

What is the best treatment for adults with Graves' disease in 2016? To answer this question, we reviewed the literature using the standard Prescrire methodology. When the symptoms of hyperthyroidism are poorly tolerated, a beta-blocker relieves tachy- cardia, anxiety and tremor. Three treatments have been shown to be effec- tive in controlling hyperthyroidism: antithyroid drugs, radioiodine, and thyroidectomy. Read More

View Article

Download full-text PDF

Source

Pegloticase: withdrawal of its European marketing authorisation is welcome.

Authors:

Prescrire Int 2017 Mar;26(180):71

View Article

Download full-text PDF

Source

Drug-induced diarrhoea.

Authors:

Prescrire Int 2017 Mar;26(180):67-71

View Article

Download full-text PDF

Source

Capsaicin (QUTENZA*) and diabetic neuropathic pain Harmful, and no tangible efficacy.

Authors:

Prescrire Int 2017 Mar;26(180):65-66

View Article

Download full-text PDF

Source
March 2017
1 Read

tedizolid (SIVEXTRO*) in skin and soft-tissue infections.

Authors:

Prescrire Int 2017 Mar;26(180):63-64

View Article

Download full-text PDF

Source
March 2017
1 Read

Secukinumab and psoriatic arthritis.

Authors:

Prescrire Int 2017 Mar;26(180):62

View Article

Download full-text PDF

Source
March 2017
1 Read

Secukinumab (Cosentyx°) and plaque psoriasis.

Authors:

Prescrire Int 2017 Mar;26(180):61-62

View Article

Download full-text PDF

Source
March 2017
1 Read

Switzerland: community pharmacists providing consultations for common medical conditions.

Authors:

Prescrire Int 2017 Feb;26(179):54-55

In Switzerland, pharmacists have set up a con- sultation service for common medical conditions in community pharmacies, in collaboration with doctors providing video consultations. Initial evaluations show the value of the service in terms of access to healthcare and the manage- ment of common health problems. Read More

View Article

Download full-text PDF

Source
February 2017

The French "transparency" database: what are the "agreements" between Prescrire and drug companies?.

Authors:

Prescrire Int 2017 Feb;26(179):52-54

View Article

Download full-text PDF

Source
February 2017
1 Read

Metastatic colorectal cancer.

Authors:

Prescrire Int 2017 Feb;26(179):51

View Article

Download full-text PDF

Source
February 2017
1 Read

Mosquito and tick bites: individual prophylaxis First-choice treatments.

Authors:

Prescrire Int 2017 Feb;26(179):48-50

View Article

Download full-text PDF

Source
February 2017
1 Read

Benfluorex: adverse effects reviewed, 1976-2015.

Authors:

Prescrire Int 2017 Feb;26(179):47

View Article

Download full-text PDF

Source
February 2017
1 Read

Long-acting injectable olanzapine: post-injection syndrome.

Authors:

Prescrire Int 2017 Feb;26(179):46

View Article

Download full-text PDF

Source
February 2017
2 Reads

Hormonal contraceptive + enzyme inducer: unintended pregnancies.

Authors:

Prescrire Int 2017 Feb;26(179):45

View Article

Download full-text PDF

Source
February 2017

Extrapyramidal disorders with domperidone.

Authors:

Prescrire Int 2017 Feb;26(179):44

View Article

Download full-text PDF

Source
February 2017

Entecavir (Baraclude°) and chronic hepatitis B in children.

Authors:

Prescrire Int 2017 Feb;26(179):42-43

View Article

Download full-text PDF

Source
February 2017

Idebenone (Raxone°) and Leber hereditary optic neuropathy.

Authors:

Prescrire Int 2017 Feb;26(179):41

View Article

Download full-text PDF

Source
February 2017
1 Read

Perampanel (Fycompa°) and refractory generalised epilepsy.

Authors:

Prescrire Int 2017 Feb;26(179):40-41

View Article

Download full-text PDF

Source
February 2017
1 Read

Mepolizumab (Nucala°) in asthma.

Authors:

Prescrire Int 2017 Feb;26(179):38-39

View Article

Download full-text PDF

Source
February 2017
1 Read

Sacubitril + valsartan (Entresto°) in chronic heart failure.

Authors:

Prescrire Int 2017 Feb;26(179):33-37

View Article

Download full-text PDF

Source
February 2017
1 Read

Taking missing data into account in everyday practice.

Authors:

Prescrire Int 2017 Jan;26(178):23-27

Ideally, health professionals would have all the necessary information at their disposal for making healthcare decisions, but in reality they lack a great deal of clinically relevant data. Some of these missing data simply cannot, or cannot yet, exist. In other cases, the data are missing because the healthcare professional was unable to find them even though they are available, because they have not been generated even though they could have been, because they have not been published, or because they have been concealed. Read More

View Article

Download full-text PDF

Source
January 2017

Hypertension Targeting 120 mmHg: survival benefit after 3 years, but high renal risk.

Authors:

Prescrire Int 2017 Jan;26(178):21-22

In a randomised trial, reducing the systolic blood pressure target to around 120 mmHg led to a reduction in all-cause mortality compared to a tar- get of around 135 mmHg: after about 3 years, 3.3% of patients in the "inten- sive" treatment group had died versus 4.5% in the "standard" treatment group. Read More

View Article

Download full-text PDF

Source
January 2017
1 Read

Pseudoephedrine: ischaemic colitis.

Authors:

Prescrire Int 2017 Jan;26(178):20

View Article

Download full-text PDF

Source
January 2017

Keppra° oral solutions of levetiracetam: cases of overdose.

Authors:

Prescrire Int 2017 Jan;26(178):19

View Article

Download full-text PDF

Source
January 2017

Statins: increased risk of type 2 diabetes.

Authors:

Prescrire Int 2017 Jan;26(178):18-19

Five meta-analyses of double-blind randomised comparative clinical trials have shown a small but statistically significant increase in the risk of type 2 diabetes in statin users. The relative risk was about 1.1. Read More

View Article

Download full-text PDF

Source
January 2017

Benzodiazepines: dementia in the elderly?.

Authors:

Prescrire Int 2017 Jan;26(178):16-17

About twenty benzodiazepines and related drugs, such as zolpidem and zopiclone, are used to treat sleep dis- orders and anxiety, and also as anti- convulsants.Their short-term adverse effects include confusion and cogni- tive disorders that regress only slow- ly after treatment withdrawal, especial- ly in elderly patients. Questions have been raised as to persistent cognitive effects in case of long-term benzo- diazepine exposure. Read More

View Article

Download full-text PDF

Source
January 2017

Sonidegib (Odomzo°) and extensive basal cell carcinoma.

Authors:

Prescrire Int 2017 Jan;26(178):14-15

View Article

Download full-text PDF

Source
January 2017

Edoxaban (Lixiana°).

Authors:

Prescrire Int 2017 Jan;26(178):13-14

View Article

Download full-text PDF

Source
January 2017